San Francisco, California, March 23, 2021—Wave 80 Biosciences today announced a major expansion of its IP portfolio with the issuance of U.S. Patent 10,955,067, Methods and Systems for Enhanced [...]
Promising results are being seen in the performance of new sample preparation modules being developed for respiratory infection, Wave 80 announced today. The significant challenges associated [...]
Multiplexed detection and quantitation of T1D-relevant autoantibodies holds significant promise for improving patient outcomes
Positioning to meet emerging needs in respiratory infection, STIs, and other high unmet need areas, Wave 80 announced further improvements in the development of its high-performance sample prep [...]
As an invited keynote speaker at today’s MedInnovations meeting, Wave 80’s Dan Laser described the role for key emerging technologies in the life sciences. In a subsequent panel [...]
Grant by United States Patent and Trademark Office covers groundbreaking Wave 80 technology for high-performance molecular assays, liquid biopsy, and other applications.
As part of the occasional Amgen Innovator Series featuring high-profile Bay Area life sciences leaders, Wave 80 founder Dan Laser spoke today at the California Institute for Quantitative [...]
On World Tuberculosis Day, Wave 80 announced the latest advances in its programs seeking to contribute to global efforts in a disease that persists as a major threat to human health around the [...]
Washington, DC, April 6, 2016—At a major gathering of leaders in the tuberculosis field, held in Washington DC, Wave 80 founder and Board of Directors chairman Dr. Daniel Laser was joined by Palu [...]
Liquid micropiston-based sample prep technology meet emerging needs around sequencing multi-drug resistant strains
